Cargando…
Hereditary Angioedema Therapy: Kallikrein Inhibition and Bradykinin Receptor Antagonism
Current strategies for the treatment of hereditary angioedema (HAE) include targeted inhibition or antagonism of the contact system, which is dysregulated in HAE patients by a C1 esterase inhibitor deficiency. Ecallantide, a plasma kallikrein inhibitor, and icatibant, a selective bradykinin-2 recept...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
World Allergy Organization
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666151/ https://www.ncbi.nlm.nih.gov/pubmed/23282868 http://dx.doi.org/10.1097/1939-4551-3-S3-S34 |